Literature DB >> 18476193

Septic shock, adult respiratory distress syndrome, and disseminated intravascular coagulopathy following midtrimester genetic amniocentesis.

J R Johnson1, P G Stubblefield, M A Hamid, J Kasznica.   

Abstract

BACKGROUND: Midtrimester genetic amniocentesis is a commonly performed procedure, with acknowledgment of some risk to mother and fetus. CASE: We present an unusual case of midtrimester genetic amniocentesis with bowel injury and resulting septic shock, adult respiratory distress syndrome, and disseminated intravascular coagulation. A total abdominal hysterectomy and bilateral salpingoophorectomy were required for resolution of sepsis. The patient also required prolonged ventilatory support postoperatively.
CONCLUSION: Although relatively safe, genetic amniocentesis can result in serious morbidity, and attention to technique should be maintained.

Entities:  

Year:  1997        PMID: 18476193      PMCID: PMC2364589          DOI: 10.1155/S1064744997000707

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  3 in total

1.  Sepsis due to Clostridium perfringens after second-trimester amniocentesis.

Authors:  Y Hovav; E Hornstein; R N Pollack; C Yaffe
Journal:  Clin Infect Dis       Date:  1995-07       Impact factor: 9.079

Review 2.  Septic abortion.

Authors:  P G Stubblefield; D A Grimes
Journal:  N Engl J Med       Date:  1994-08-04       Impact factor: 91.245

3.  Mid-second-trimester labor induction: concentrated oxytocin compared with prostaglandin E2 vaginal suppositories.

Authors:  C L Winkler; S E Gray; J C Hauth; J Owen; J M Tucker
Journal:  Obstet Gynecol       Date:  1991-02       Impact factor: 7.661

  3 in total
  1 in total

1.  Impact of fetal maceration grade on risk of maternal disseminated intravascular coagulation after intrauterine fetal death - A retrospective cohort study.

Authors:  Dana A Muin; Helmuth Haslacher; Vanessa Koller; Herbert Kiss; Anke Scharrer; Alex Farr
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.